| 1. |
- Hanrieder, Jörg, 1980, et al.
(författare)
-
MALDI imaging mass spectrometry: Neurochemical imaging of proteins and peptides
- 2019
-
Ingår i: Neuroproteomics. Ka Wan Li (red.). - New York, NY : Springer. - 0893-2336 .- 1940-6045. - 9781493996612 ; , s. 179-197
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- © Springer Science+Business Media, LLC, part of Springer Nature 2019. The central nervous system (CNS) constitutes the most intricate tissue in the human body. Neurological diseases, in particular, have a complex pathophysiology and are heterogeneous in their pathological and clinical presentation and therefore poorly understood on a molecular level. Increased insight in molecular CNS disease pathophysiology relates directly to the advancement of novel bioanalytical technologies that allow highly resolved, sensitive, specific, and comprehensive molecular analysis and molecular imaging in complex biological tissues, and in the CNS in particular. Imaging mass spectrometry (IMS) is an emerging technique for molecular imaging, characterized by its high molecular specificity and is therefore a powerful approach for investigating molecular localization patterns in CNS-derived tissue and cells. Over the last 20 years, IMS has been demonstrated to be a promising technology for chemical imaging in biochemical studies, but its application in clinical research is still in its infancy. The goal of this chapter is to provide the reader with a detailed step-by-step guide through the IMS workflow for the successful replication of published experimental data. Moreover, the aim is to give a concise overview of the major developments and applications of matrix-assisted laser desorption ionization (MALDI) based imaging mass spectrometry for neurochemical profiling with particular focus on protein and peptide imaging in neurodegenerative disease pathology.
|
|
| 2. |
- Lista, S, et al.
(författare)
-
Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease
- 2017
-
Ingår i: Dementia. David Ames, John T. O'Brien, Alistair Burns (red.). - Boca Raton : CRC Press. - 9781498703116 ; , s. 528-538
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80% (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions
|
|
| 3. |
- Rosén, Christoffer, 1986, et al.
(författare)
-
Alzheimer’s disease and other neurodegenerative disorders
- 2015
-
Ingår i: Cerebrospinal Fluid in Clinical Neurology. - Cham : Springer. - 9783319012254 ; , s. 329-351
-
Bokkapitel (refereegranskat)abstract
- Traditionally, patients suffering from Alzheimer’s disease (AD) have been diagnosed according to clinical criteria, and a diagnosis has only been made in the dementia stage of the disease. Defi nite diagnosis required autopsy to confi rm the neuropathological fi ndings associated with AD, namely, extracellular depositions of amyloid a (Aa) protein and intraneuronal neurofi brillary tangles consisting of hyperphosphorylated tau (P-tau) protein, together with gross cortical atrophy caused by neuronal degeneration and loss. These fi ndings are refl ected in the cerebrospinal fl uid (CSF) of patients with AD. Numerous studies have shown that AD patients have lower levels of Aa42 and higher levels of P-tau and total tau (T-tau) in CSF than cognitively healthy controls. In the new diagnostic criteria for AD, these CSF biomarkers are included as in vivo evidence of AD neuropathology together with positron emission tomography (PET) measurements of global cortical amyloid load. Further, AD is now divided into several disease stages, namely, preclinical AD and mild cognitive impairment and dementia due to AD. In this chapter, we review CSF biomarker characteristics for the various disease stages for AD and how to use them in the differentiation against other common neurodegenerative disorders. New candidate CSF biomarkers for AD are also presented, as well as a discussion on the standardization of biomarkers and their application in clinical trials. © Springer International Publishing Switzerland 2015.
|
|
| 4. |
- Zetterberg, Henrik, 1973, et al.
(författare)
-
Fluid Biomarkers and Diagnostics
- 2016
-
Ingår i: Developing Therapeutics for Alzheimer's Disease / edited by: Michael S. Wolfe. - Amsterdam : Elsevier. - 9780128021736 ; , s. 565-587
-
Bokkapitel (refereegranskat)
|
|
